菜单
Telephone sharing button Contact Us linkedin sharing button LinkedIn wechat sharing button YouTube wechat sharing button Twitter mailbox sharing button ps_marketing@wuxibiologics.com
arrow_left sharing button
arrow_right sharing button
CRO Services

Drug Development Expertise Empowering Research Services for Biologics

Autoimmune & Inflammation Assays


Comprehensive Autoimmune & Inflammation Bioassays for Biologics Development

WuXi Biologics provides industry-leading autoimmune and inflammation bioassays to support antibody characterization, functional screening, and mechanism of action (MOA) studies. Our comprehensive in vitro assays assess immune cell modulation, cytokine profiling, and Fc effector functions, ensuring full characterization of autoimmune and inflammation targets.

 

Our autoimmune & inflammatory assays include:

  • High-throughput, customizable cell-based assays for lead optimization
  • MOA evaluations via ligand competition assays, reporter gene assays, and more
  • Comprehensive Fc effector function assays (ADCC, ADCP & CDC)
  • Evaluation of PBMC activation, cytokine profiling, and antigen-specific immune response
  • Ex vivo immunogenicity assays for in vitro safety evaluation, including CD134+/CD137+ T cell activation by FACS and IFN-γ detection assays by enhanced ELISPOT

Industry-leading autoimmune and inflammation bioassays to support antibody characterization, functional screening, and mechanism of action (MOA) studies.

Autoimmune & Inflammation Assay Details:

Service Item Description Request A Quote 
Reporter Gene Assay (RGA)​

Immune checkpoint assays

Bispecific antibody RGA

Fc Effector Function: ADCC, ADCP

Request A Quote
PBMC Activation

Anti-CD3/CD28 stimulation​

Super antigen stimulation

Cytokine release detection​

T/NK/B Cell Activation, Expansion and Signal pathway Detection​

Western blot

p-ELISA/HTRF/AlphaLISA/FACS

Activation biomarkers (FACS)

Fc-dependent Killing and Phagocytosis Assay​

ADCC (FACS/LDH/RGA)

ADCP (FACS/RGA)​

CDC​

Allogeneic Mixed Lymphocytes Reaction

Schedule a Free Consultation

Antigen-Specific MLR/T Cell Recall Assay Schedule a Free Consultation
T Cell Exhaustion​ Schedule a Free Consultation
Regulatory T Cell Assay

In vitro expansion​

T cell activation-suppression assay​

Cytokine/Chemokine Profiling​

ELISA/AlphaLISA/Elispot/CBA/MSD

Apoptosis Assay​

PI/AnnexinV staining FACS​

Caspase 3/7 activation (Luminescence)​

Differentiation and Polarization​

Dendritic cell differentiation

Macrophage differentiation/polarization

T cell polarization

Surface Marker Profiling​

Schedule a Free Consultation

In Vitro Safety Evaluation​

Immunogenicity evaluation​

Pre-ADA evaluation​

Cytokine release assay

Fc Effector Function Assays: ADCC, ADCP & CDC

We have developed robust antibody-dependent cellular cytotoxicity (ADCC), complement-dependent cytotoxicity (CDC), and antibody-dependent cellular phagocytosis (ADCP) assays to assess the functional activity of various antibodies. ADCC and ADCP assays utilize primary cell-based functional screening, while CDC assays are performed using a human serum mixture from multiple donors.

 

Assessing antibody Fc effector functions using ADCC, CDC, and ADCP assays.

 

In Vitro Characterization of Autoimmune and Inflammatory Targets

We offer a wide range of in vitro assays to evaluate the functional activity of leads targeting autoimmune and inflammatory diseases. Our approach includes ligand competitive binding assays, reporter gene assays (RGAs), and proliferation & immune assays, providing a comprehensive assessment of antibody efficacy and MOA.

 

In vitro autoimmune and inflammatory bioassays, including ligand competitive binding, reporter gene assays, and proliferation & immune assays.

 

Case Study #1: Inhibition of IL-31-Dependent Cell Proliferation

In this case study, we developed an assay to assess IL-31-dependent cell proliferation. Results showed that the target antibody effectively inhibited IL-31-induced cell proliferation.

 

Case study on assay development to assess IL-31-dependent cell proliferation, showing that the target antibody effectively inhibited IL-31-induced cell proliferation.

Figure 1: (A) BMK1 antibody significantly inhibited IL-31-dependent proliferation of BaF3 cells expressing two receptors. (B) BMK1 antibody demonstrated an IC50 of 0.071 nM and a maximum inhibition of 102%, whereas the isotype control showed minimal inhibition.

Case Study #2: Inhibition of IL-4-Induced CD23 Upregulation in B Cells

In this case study, we developed a FACS binding assay to assess the inhibition of IL-4-induced CD23 expression on B cells. The results demonstrated the potential of both antibodies to suppress B cell activation mediated by the IL-4/IL-4R signaling pathway.

Case study on FACS-based binding assay to assess inhibition of IL-4-induced CD23 upregulation on B cells, demonstrating the potential of both antibodies to suppress B cell activation via the IL-4/IL-4R signaling pathway.

Figure 1: (A) Scheme of the IL-4/IL-4R signaling pathway, which induces CD23 expression on B cells. (B) Antibody 1 and Antibody 2 effectively inhibited B cell activation induced by activating IL-4/IL-4R signaling pathway compared to hIgG4 isotype control.

Case Study #3: Inhibition of CD40L-Induced B Cell Proliferation

This case study presents an assay developed to assess CD40L-induced B cell proliferation and its inhibition in a dose-dependent manner.

Case study on assay development to assess CD40L-induced B cell proliferation and its inhibition by therapeutic antibody candidates in a dose-dependent manner.

Figure 1: (A) Scheme of the antibody interaction between CD40L on T cells and CD40 on B cells, leading to the inhibition of B cell proliferation. (B) Both anti-CD40 antagonists 1 and 2 significantly reduced CD40L-induced B cell proliferation compared to human IgG1 isotype control.

Case Study #4: CD134+/CD137+ CD4+ T Cell Activation by FACS

In this case study, we developed an assay to assess CD134+ /CD137+ CD4+ T cell activation by different antibodies or antigens, with CD134 (OX40) and CD137 (4-1BB) contributing to CD4+ T helper cell activation following stimulation. The proportion of cells positive for CD134 and/or CD137 distinguished biotherapeutics with low immunogenicity from those with intermediate or high immunogenicity.

Figure 1: (A) The proportion of CD4+ T cells positive for CD134 and/or CD137. (B) The scatter plot representing the stimulation index (SI) of the 50 donors tested. (C) The bar graph representing the percentage of positive PMBC activation from 50 donors.

Case Study #5: IFN-γ Detection Assay by Enhanced ELISPOT

In this case study, we developed an assay to assess IFN-γ release after T cell activated by different antibodies using enhanced ELISPOT.

Figure 1: (A) Scheme of the IFN-γ detection assay by enhanced ELISPOT. (B) The scatter plot representing the IFN-γ spot forming per million PBMCs from each of the 34 donors tested.

Your Project. Our Expertise.